{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:49:41Z","timestamp":1790952581861,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Perinatol"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical trials are essential to test the safety and efficacy of new treatments in any population. The paucity of drug trials especially in the neonatal population has led to the widespread use of unlicensed or off-label medications, exposing them to the risks of drug toxicity and ineffective treatment. Ethical and operational challenges are no longer considered valid excuses for not conducting drug trials in neonates. We recently participated in a combined phase-2 and phase-3 trial investigating a new indigenous goat lung surfactant extract (GLSE) for the treatment of respiratory distress syndrome (RDS) in preterm neonates. In this article, we share pertinent challenges faced by us during the trial to better inform and foster-positive discussion among drug developers, administrators, regulatory authorities, patient advocacy groups, and researchers. Also, we provide many tools developed for the GLSE trial that can be modified and used by prospective trialists.<\/jats:p>","DOI":"10.1038\/s41372-019-0469-8","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T12:04:12Z","timestamp":1567598652000},"page":"20-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Issues, challenges, and the way forward in conducting clinical trials among neonates: investigators\u2019 perspective"],"prefix":"10.1038","volume":"39","author":[{"given":"Sindhu","family":"Sivanandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishad","family":"Plakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanushree","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirshendu","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogendra Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"469_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijcard.2017.01.018","volume":"232","author":"C Vitale","year":"2017","unstructured":"Vitale C, Fini M, Spoletini I, Lainscak M, Seferovic P, Rosano GM. Under-representation of elderly and women in clinical trials. Int J Cardiol. 2017;232:216\u201321.","journal-title":"Int J Cardiol"},{"key":"469_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/bcp.13497","volume":"84","author":"G Labots","year":"2018","unstructured":"Labots G, Jones A, de Visser SJ, Rissmann R, Burggraaf J. Gender differences in clinical registration trials: is there a real problem? Br J Clin Pharm. 2018;84:700\u20137.","journal-title":"Br J Clin Pharm"},{"key":"469_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-014-1768-9","volume":"71","author":"J Magalhaes","year":"2015","unstructured":"Magalhaes J, Rodrigues AT, Roque F, Figueiras A, Falcao A, Herdeiro MT. Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review. Eur J Clin Pharm. 2015;71:1\u201313.","journal-title":"Eur J Clin Pharm"},{"key":"469_CR4","doi-asserted-by":"publisher","first-page":"e0204427","DOI":"10.1371\/journal.pone.0204427","volume":"13","author":"H Costa","year":"2018","unstructured":"Costa H, Costa TX, Martins RR, Oliveira AG. Use of off-label and unlicensed medicines in neonatal intensive care. PLoS ONE. 2018;13:e0204427.","journal-title":"PLoS ONE"},{"key":"469_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/bcp.12467","volume":"79","author":"MA Turner","year":"2015","unstructured":"Turner MA. Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct. Br J Clin Pharm. 2015;79:370\u20138.","journal-title":"Br J Clin Pharm"},{"key":"469_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","volume":"3","author":"E Fernandez","year":"2011","unstructured":"Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3:53\u201372.","journal-title":"Pharmaceutics"},{"key":"469_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/17512433.2018.1439378","volume":"11","author":"K Allegaert","year":"2018","unstructured":"Allegaert K, Smits A, van den Anker JN. Drug evaluation studies in neonates: how to overcome the current limitations. Expert Rev Clin Pharm. 2018;11:387\u201396.","journal-title":"Expert Rev Clin Pharm"},{"key":"469_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamapediatrics.2013.4604","volume":"168","author":"JL Stiers","year":"2014","unstructured":"Stiers JL, Ward RM. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pedia. 2014;168:106\u20138.","journal-title":"JAMA Pedia"},{"key":"469_CR9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJMp048361","volume":"352","author":"S Nundy","year":"2005","unstructured":"Nundy S, Gulhati CM. A new colonialism?-Conducting clinical trials in India. N Engl J Med. 2005;352:1633\u20136.","journal-title":"N Engl J Med"},{"key":"469_CR10","doi-asserted-by":"publisher","first-page":"22450","DOI":"10.3402\/gha.v6i0.22450","volume":"6","author":"RF Viergever","year":"2013","unstructured":"Viergever RF. The mismatch between the health research and development (R&D) that is needed and the R&D that is undertaken: an overview of the problem, the causes, and solutions. Glob Health Action. 2013;6:22450.","journal-title":"Glob Health Action"},{"key":"469_CR11","doi-asserted-by":"publisher","first-page":"c1775","DOI":"10.1136\/bmj.c1775","volume":"340","author":"G Mudur","year":"2010","unstructured":"Mudur G. Human papillomavirus vaccine project stirs controversy in India. BMJ. 2010;340:c1775.","journal-title":"BMJ"},{"key":"469_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/injr.injr_110_17","volume":"13","author":"S Lahiry","year":"2018","unstructured":"Lahiry S, Sinha R, Choudhury S, Mukherjee A, Chatterjee S. Paradigm shift in clinical trial regulations in India. Indian J Rheumatol. 2018;13:51\u20135.","journal-title":"Indian J Rheumatol"},{"key":"469_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/ija.IJA_143_17","volume":"61","author":"NJ Gogtay","year":"2017","unstructured":"Gogtay NJ, Ravi R, Thatte UM. Regulatory requirements for clinical trials in India: What academicians need to know. Indian J Anaesth. 2017;61:192\u20139.","journal-title":"Indian J Anaesth"},{"key":"469_CR14","first-page":"1","volume":"5","author":"T Burt","year":"2014","unstructured":"Burt T, Sharma P, Dhillon S, Manchanda M, Mittal S, Trehan N. Clinical research environment in India: challenges and proposed solutions. J Clin Res Bioeth. 2014;5:1\u20138.","journal-title":"J Clin Res Bioeth"},{"key":"469_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/jphi.JPHI_31_17","volume":"7","author":"M Urooj","year":"2017","unstructured":"Urooj M, Husain GM, Khan MA, Kazmi MH. Compensation to clinical trial participants in India: a gap analysis. Int J Pharm Invest. 2017;7:41\u20136.","journal-title":"Int J Pharm Invest"},{"issue":"S1","key":"469_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41372-019-0472-0","volume":"39","author":"Kajal Jain","year":"2019","unstructured":"Jain K, Nangia S, Bhat BV, Sundaram S, Jeeva Sankar M, Ramji S, et al. Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multisite randomized non-inferiority trial. J Perinatol. 2019;39:3\u201312.","journal-title":"Journal of Perinatology"},{"key":"469_CR17","unstructured":"The Central Drugs Standard Control Organisation (CDSCO). Report of the Prof. Ranjit Roy Chaudhury expert committee to formulate policy and guidelines for approval of new drugs, clinical trials and banning of drugs; 2013 [cited 1 Nov 2018] Available from: http:\/\/www.cdsco.nic.in\/writereaddata\/Report_of_Dr_Ranjit_Roy.pdf"},{"key":"469_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4103\/2395-5414.166344","volume":"1","author":"S Seth","year":"2015","unstructured":"Seth S. Health Ministry Screening Committee (Indian Council of Medical Research). J Pract Cardiovasc Sci. 2015;1:216\u20137.","journal-title":"J Pract Cardiovasc Sci"},{"key":"469_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/2229-3485.96444","volume":"3","author":"R Kadam","year":"2012","unstructured":"Kadam R, Karandikar S. Ethics committees in India: facing the challenges! Perspect Clin Res. 2012;3:50\u20136.","journal-title":"Perspect Clin Res"},{"key":"469_CR20","unstructured":"The Central Drugs Standard Control Organisation (CDSCO). The Gazette of India. New Delhi: Ministry of Health and Welfare Notification. [General Statutory Rules 611 (E)]; 2015. 31 Jul 2015 [cited 1 Nov 2018] Available from: http:\/\/www.cdsco.nic.in\/writereaddata\/Gazette%20Notification%2031%20July%202015.pdf"},{"key":"469_CR21","unstructured":"Indian Council of Medical Research. National ethical guidelines for biomedical research involving human particpants. 2017 [cited 2017] Available from: https:\/\/www.icmr.nic.in\/sites\/default\/files\/guidelines\/ICMR_Ethical_Guidelines_2017.pdf"},{"key":"469_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4103\/picr.PICR_172_17","volume":"9","author":"PA Shetty","year":"2018","unstructured":"Shetty PA, Maurya MR, Figer BH, Thatte UM, Gogtay NJ. Audiovisual recording of the consenting process in clinical research: experiences from a tertiary referral center. Perspect Clin Res. 2018;9:44\u20137.","journal-title":"Perspect Clin Res"},{"key":"469_CR23","unstructured":"Ministry of Health and Family Welfare. Govt of India. Notification. The Gazette of India: Extraordinary, Part II, Section 3, Subsection (i), New Delhi: 2019 Mar 19 [cited 17 Aug 2019], pp 1\u2013264. Available from: https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/NewDrugs_CTRules_2019.pdf"},{"key":"469_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.7897\/2277-4343.04612","volume":"4","author":"P Dua","year":"2013","unstructured":"Dua P, Dua P. Recent chanfes in the clinical trials regulatory framework in India; The road for AYUSH sector. Int J Res Ayurveda Pharm. 2013;4:841\u20136.","journal-title":"Int J Res Ayurveda Pharm"},{"key":"469_CR25","unstructured":"The use of the WHO\u2013UMC system for standardised case causality assessment. [cited 1 Nov 2018] Available from: http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf"},{"key":"469_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"469_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-014-0230-3","volume":"37","author":"YK Gupta","year":"2014","unstructured":"Gupta YK, Pradhan AK, Goyal A, Mohan P. Compensation for clinical trial-related injury and death in India: challenges and the way forward. Drug Saf. 2014;37:995\u20131002.","journal-title":"Drug Saf"},{"key":"469_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-845","volume":"7","author":"MM Ngari","year":"2014","unstructured":"Ngari MM, Waithira N, Chilengi R, Njuguna P, Lang T, Fegan G. Experience of using an open source clinical trials data management software system in Kenya. BMC Res Notes. 2014;7:845.","journal-title":"BMC Res Notes"},{"key":"469_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.conctc.2016.08.002","volume":"4","author":"C Madeira","year":"2016","unstructured":"Madeira C, Pais A, Kubiak C, Demotes J, Monteiro EC. Investigator-initiated clinical trials conducted by the Portuguese Clinical Research Infrastructure Network (PtCRIN). Conte Clin Trials Commun. 2016;4:141\u20138.","journal-title":"Conte Clin Trials Commun"},{"key":"469_CR30","unstructured":"The Central Drugs Standard Control Organisation (CDSCO). Sugam- CDSCO Portal for Online Application; 2015 [cited 1 Nov 2018] Available from: http:\/\/www.cdsco.nic.in\/writereaddata\/SUGAM%20PORTAL%20APPLICATIONS.pdf"},{"key":"469_CR31","unstructured":"National Institutes of Health Single IRB Policy for Multi-site Research https:\/\/grants.nih.gov\/policy\/humansubjects\/single-irb-policy-multi-site-research.htm"},{"key":"469_CR32","first-page":"181","volume":"11","author":"MS Kuyare","year":"2014","unstructured":"Kuyare MS, Taur SR, Thatte UM. Establishing institutional ethics committees: challenges and solutions\u2014a review of the literature. Indian J Med Ethics. 2014;11:181\u20135.","journal-title":"Indian J Med Ethics"},{"key":"469_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-8847.2012.00340.x","volume":"14","author":"MO Folayan","year":"2014","unstructured":"Folayan MO, Adaranijo A, Durueke F, Ajuwon A, Adejumo A, Ezechi O, et al. Impact of three years training on operations capacities of research ethics committees in Nigeria. Dev World Bioeth. 2014;14:1\u201314.","journal-title":"Dev World Bioeth"},{"key":"469_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/2229-3485.198549","volume":"8","author":"UM Thatte","year":"2017","unstructured":"Thatte UM, Marathe PA. Ethics Committees in India: past, present and future. Perspect Clin Res. 2017;8:22\u201330.","journal-title":"Perspect Clin Res"},{"key":"469_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/cpt.514","volume":"100","author":"MR Trusheim","year":"2016","unstructured":"Trusheim MR, Shrier AA, Antonijevic Z, Beckman RA, Campbell RK, Chen C, et al. PIPELINEs: creating comparable clinical knowledge efficiently by linking trial platforms. Clin Pharmacol Ther. 2016;100:713\u201329.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41372-019-0469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41372-019-0469-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41372-019-0469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:29:15Z","timestamp":1684603755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41372-019-0469-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":35,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1038\/s41372-019-0469-8","relation":{},"ISSN":["0743-8346","1476-5543"],"issn-type":[{"value":"0743-8346","type":"print"},{"value":"1476-5543","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"4 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}